How have DRMA shares performed in 2024?

Dermata Therapeutics' stock was trading at $0.61 at the beginning of 2024. Since then, DRMA stock has decreased by 47.4% and is now trading at $0.3206. View the best growth stocks for 2024 here .

Are investors shorting Dermata Therapeutics?

Dermata Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 101,800 shares, an increase of 42.6% from the March 15th total of 71,400 shares. Based on an average daily trading volume, of 616,200 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.7% of the company's shares are sold short. View Dermata Therapeutics' Short Interest .

When is Dermata Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our DRMA earnings forecast .

How were Dermata Therapeutics' earnings last quarter?

Dermata Therapeutics, Inc. (NASDAQ:DRMA) posted its earnings results on Thursday, March, 21st. The company reported ($0.21) EPS for the quarter.

When did Dermata Therapeutics' stock split?

Dermata Therapeutics's stock reverse split before market open on Tuesday, March 14th 2023. The 1-16 reverse split was announced on Tuesday, March 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did Dermata Therapeutics IPO?

Dermata Therapeutics (DRMA) raised $18 million in an initial public offering (IPO) on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share.

How do I buy shares of Dermata Therapeutics?

Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DRMA

Dermata Therapeutics (DRMA) Stock Price, News & Analysis

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Free DRMA Stock Alerts

$0.34

+0.04 (+14.68%)

(As of 05:17 PM ET)

Compare

Today's Range: $0.29
▼
$0.36
50-Day Range: $0.28
▼
$0.47
52-Week Range: $0.23
▼
$3.68

Volume: 277,234 shs
Average Volume: 737,616 shs
Market Capitalization: $2.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Dermata Therapeutics alerts:

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Dermata Therapeutics Stock (NASDAQ:DRMA)

Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

DRMA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DRMA Stock News Headlines

April 10, 2024 | americanbankingnews.com

Dermata Therapeutics (NASDAQ:DRMA) Trading Down 3%

February 11, 2024 | ca.finance.yahoo.com

Dermata Therapeutics, Inc. (DRMAW)

April 18, 2024 | DTI (Ad)

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

February 6, 2024 | finance.yahoo.com

Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now

February 4, 2024 | morningstar.com

Dermata Therapeutics Inc DRMA

February 1, 2024 | finance.yahoo.com

Dermata to Present at the Emerging Growth Conference on February 7, 2024

January 7, 2024 | msn.com

Dermata stock soars on patent issuance, partnership talks

January 5, 2024 | msn.com

Dow Turns Lower; ISM Services PMI Falls In December

April 18, 2024 | DTI (Ad)

A new way to collect income from stocks

January 5, 2024 | msn.com

Why Is Aesthetic Skin Conditions-Focused Dermata Therapeutics Stock Trading Higher Today?

January 5, 2024 | investorplace.com

Why Is Dermata Therapeutics (DRMA) Stock Up 62% Today?

January 4, 2024 | marketwatch.com

Stocks to Watch: Dermata Therapeutics, Applied Therapeutics, Fusion Pharmaceuticals

January 4, 2024 | marketwatch.com

Dermata Therapeutics Shares Surge 120% on Patent Issued in Japan

January 4, 2024 | msn.com

Why Dermata Therapeutics Stock Took Off After-Hours

January 4, 2024 | finance.yahoo.com

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

December 21, 2023 | finanznachrichten.de

Dermata Therapeutics: Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

December 20, 2023 | benzinga.com

Dermata Therapeutics Stock (NASDAQ:DRMA) Dividends: History, Yield and Dates

December 20, 2023 | finance.yahoo.com

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

December 13, 2023 | thestreet.com

Dermata Therapeutics Inc.

November 16, 2023 | finance.yahoo.com

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

November 16, 2023 | finance.yahoo.com

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

November 10, 2023 | msn.com

Dermata Therapeutics GAAP EPS of -$0.54

November 9, 2023 | finance.yahoo.com

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

October 26, 2023 | finance.yahoo.com

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

August 31, 2023 | finance.yahoo.com

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 11, 2023 | finance.yahoo.com

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

June 27, 2023 | finance.yahoo.com

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

See More Headlines

Receive DRMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:DRMA
CUSIP: N/A
CIK: 1853816
Web: www.dermatarx.com
Phone: 858-800-2543
Fax: N/A
Employees: 8
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,800,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -107.95%
Return on Assets: -93.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.91
Quick Ratio: 4.91

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.62 per share
Price / Book: 0.20

Miscellaneous

Outstanding Shares: 6,660,000
Free Float: 6,035,000
Market Cap: $2.14 million
Optionable: Not Optionable
Beta: 0.87

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Gerald T. Proehl (Age 65)
Founder, President, CEO & Chairman
Comp: $392k
Mr. David F. Hale (Age 75)
Co-Founder & Lead Independent Director
Comp: $73k
Dr. Christopher J. Nardo M.P.H. (Age 59)
Ph.D., Senior VP & Chief Development Officer
Comp: $443.52k
Mr. Sean Proehl
Senior Director of Legal & Business Development
Dr. Maria Bedoya Toro Munera M.B.A. (Age 73)
Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance
Comp: $27.04k

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Bought 218,000 shares on 2/13/2024
Ownership: 6.158%

View All Institutional Transactions

DRMA Stock Analysis - Frequently Asked Questions

How have DRMA shares performed in 2024?: Dermata Therapeutics' stock was trading at $0.61 at the beginning of 2024. Since then, DRMA stock has decreased by 47.4% and is now trading at $0.3206.
View the best growth stocks for 2024 here.
Are investors shorting Dermata Therapeutics?: Dermata Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 101,800 shares, an increase of 42.6% from the March 15th total of 71,400 shares. Based on an average daily trading volume, of 616,200 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.7% of the company's shares are sold short.
View Dermata Therapeutics' Short Interest.
When is Dermata Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our DRMA earnings forecast.
How were Dermata Therapeutics' earnings last quarter?: Dermata Therapeutics, Inc. (NASDAQ:DRMA) posted its earnings results on Thursday, March, 21st. The company reported ($0.21) EPS for the quarter.

When did Dermata Therapeutics' stock split?: Dermata Therapeutics's stock reverse split before market open on Tuesday, March 14th 2023. The 1-16 reverse split was announced on Tuesday, March 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.
When did Dermata Therapeutics IPO?: Dermata Therapeutics (DRMA) raised $18 million in an initial public offering (IPO) on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share.
How do I buy shares of Dermata Therapeutics?: Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRMA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial